

Introducing mmOligo

Direct RNA Sequencing by Mass Spectrometry


mmOligo seeks to improve reliability and speed up the development of lifesaving and life-enhancing oligonucleotide-based therapeutics.

Direct sequencing via mass spectrometry has become essential for the development and QA/QC for manufacturing of highly modified and highly complex oligonucleotide-based therapeutics.

Our team of scientists and software developers is delivering semi-automated direct sequencing solutions for the analysis of oligonucleotides by mass spectrometry.

Key Advantages of mmOligo

- Best in class sequencing of oligonucleotides¹.
- Expanded capabilities for sequencing hybrid and conjugated oligonucleotides².
- Interoperable data standard.



<u>MassMatrix, Inc</u>. is a Data Analytics and Bioinformatics Software company that specializes in developing custom solutions to complex biodata analysis problems.

Join our technical advising team to develop the best platform for Sequencing and Characterization of RNA Therapeutics.



The Science Behind MassMatrix

1. **Spacer Fidelity Assessments of Guide RNA by Top-Down Mass Spectrometry.** Luis A. Macias, Sara P. Garcia, Kayla M. Back, Yue Wu, G. Hall Johnson, Sekar Kathiresan, Andrew M. Bellinger, Ellen Rohde, Michael A. Freitas, and James A. Madsen* ACS Cent. Sci. 2023, XXXX, Publication Date: July 11, 2023. https://doi.org/10.1021/acscentsci.3c00289

2. NIH SBIR 1R44GM152984: Accelerating Gene Therapy and Editing with Advanced MS-Based Data Analysis for Nonstandard and Hybrid Nucleotide Sequences

Product development is accelerated by peer reviewed science and supported by an NIH SBIR grant to advance critical research to expand the capabilities of mmOligo. Through novel data analysis workflows we are improving the accuracy and reliability of oligonucleotide sequencing and alleviating the bottleneck in data analysis.

USASGUASIAGGU SURUKUU						
Ivanalogian Type	Miland	Elect Men		d Waters		Manu Annumary
Internatiogram Type B*	2	Eller Frideric		C 1000		0.02 Oa
P	3	.				line Trave
				#7-2	934+01,70+1.71+36	-
909 209						Minimum Scores
				Male		0.80
الأشتر الأربية فالأت						Securice Stat
15	87 55	80 40		47	43	
		tine				Sequence End
				m/v=TB2/2	Phintersity-6. Kite (25	
						Prognent Langth
40	N'N' WALL					hadada
						B,A ANALYS
20 (c.4c) m ⁻		aller bit at				
20 20 20 10 10 10 10 10 10 10 10 10 1			 til two	jî. A	- 200/ 1-1-0-0-1 900	
			tilles	Partition in the laster	WIE without which	
				mallionis (Manhallio) 20030 291.9/27	908 308 8.0039	
				1.0010 251.5/27 5.0013 290.4014	908 908 8.0039 8.0039 8.0049	
	enter a construction of the second se		1 201 10 20 20 20 20 20 20 20 20 20 20 20 20 20	14480000 1544014400 20030 251.5/27 20042 260.4018 2002 260.3018	1.0020 1.0020 1.0020 1.0020 1.0043	
			1 70.000 70.000 70.000 70.000	10000 251.5/27 2.0832 261.5/27 2.0813 280.4016 0.0802 265.3985 0.0802 0.08%	908 508 8.008 8.008 8.008 8.008 8.008	
	enter a construction of the second se		1 70.000 70.000 70.000 70.000	14480000 1544014400 20030 251.5/27 20042 260.4018 2002 260.3018	1.0020 1.0020 1.0020 1.0020 1.0043	
20 0 0 0 0 0 0 0 0 0 0 0 0 0			1 75.850 76.850 76.855 76.855	10000 251.5/27 2.0832 261.5/27 2.0813 280.4016 0.0802 265.3985 0.0802 0.08%	908 508 8.008 8.008 8.008 8.008 8.008	

Learn more about how we can help with your data and analysis workflow:

Contact us at www.massmatrix.bio

Email to sales@massmatrix.bio